Quipt Home Medical (NASDAQ:QIPT) vs. ReShape Lifesciences (NASDAQ:RSLS) Head-To-Head Contrast

Quipt Home Medical (NASDAQ:QIPT) and ReShape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

42.8% of Quipt Home Medical shares are held by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are held by institutional investors. 4.2% of Quipt Home Medical shares are held by insiders. Comparatively, 0.1% of ReShape Lifesciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Quipt Home Medical has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Earnings and Valuation

This table compares Quipt Home Medical and ReShape Lifesciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quipt Home Medical	$255.81 million	0.46	-$2.78 million	($0.11)	-24.73
ReShape Lifesciences	$8.68 million	0.33	-$11.39 million	N/A	N/A

Quipt Home Medical has higher revenue and earnings than ReShape Lifesciences.

Analyst Ratings

This is a summary of recent recommendations for Quipt Home Medical and ReShape Lifesciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quipt Home Medical	1	0	3	2	3.00
ReShape Lifesciences	0	1	0	0	2.00

Quipt Home Medical currently has a consensus target price of $6.25, indicating a potential upside of 129.78%. Given Quipt Home Medical’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Quipt Home Medical is more favorable than ReShape Lifesciences.

Profitability

This table compares Quipt Home Medical and ReShape Lifesciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quipt Home Medical	-1.95%	-4.51%	-2.01%
ReShape Lifesciences	-112.11%	-208.37%	-108.96%

Summary

Quipt Home Medical beats ReShape Lifesciences on 12 of the 13 factors compared between the two stocks.

About Quipt Home Medical

Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.

About ReShape Lifesciences

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.